- Could You Spot the Silent Symptoms of Stress?
- Gas Stoves Could Leave Your Lungs Vulnerable to Nitrogen Dioxide
- Key Therapy Equally Effective for Women, Men With Narrowed Leg Arteries
- Doctors Describe Texas Dairy Farm Worker’s Case of Bird Flu
- Does Preschool Boost Kids’ Long-Term Academic Success? Study Finds Mixed Results
- AI Might Spot Rare Diseases in Patients Years Earlier
- An Orangutan Healed Himself With Medicinal Plant
- Quit-Smoking Meds Not Working for You? Try Upping the Dose
- Fewer Americans Are Suffering Most Dangerous Form of Heart Attack
- Even Skipping Meat for One Meal Helps Liver Disease Patients
Otezla Approved for Psoriatic Arthritis
Otezla (apremilast) has been approved by the U.S. Food and Drug Administration to treat adults with active psoriatic arthritis, a condition associated with the autoimmune skin disease psoriasis.
Most people develop psoriasis first and are subsequently diagnosed with psoriatic arthritis. Common symptoms of the latter are joint pain, stiffness and swelling.
Otezla was evaluated in clinical studies involving nearly 1,500 people with active psoriatic arthritis. In a Friday news release, the FDA said Otezla users should be monitored carefully for unexplained weight loss or signs of depression. Pregnant women must register for the drug’s use, the agency added.
The most common side effects noted during clinical testing included diarrhea, nausea and headache.
Otezla is produced for Celgene Corp., based in Summit, N.J.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.